Literature DB >> 34897740

Nutrition challenges of cancer cachexia.

Omnia U Gaafer1, Teresa A Zimmers1,2,3,4,5,6.   

Abstract

Cancer cachexia, or progressive weight loss, often despite adequate nutrition contributes greatly to cancer morbidity and mortality. Cachexia is metabolically distinct from starvation or protein malnutrition, although many patients with cancer and cachexia exhibit lowered appetite and food consumption. Tumors affect neural mechanisms that regulate appetite and energy expenditure, while promoting wasting of peripheral tissues via catabolism of cardiac and skeletal muscle, adipose, and bone. These multimodal actions of tumors on the host suggest a need for multimodal interventions. However, multiple recent consensus guidelines for management of cancer cachexia differ in treatment recommendations, highlighting the lack of effective, available therapies. Challenges to defining appropriate nutrition or other interventions for cancer cachexia include lack of consensus on definitions, low strength of evidence from clinical trials, and a scarcity of robust, rigorous, and mechanistic studies. However, efforts to diagnose, stage, and monitor cachexia are increasing along with clinical trial activity. Furthermore, preclinical models for cancer cachexia are growing more sophisticated, encompassing a greater number of tumor types in organ-appropriate contexts and for metastatic disease to model the clinical condition more accurately. It is expected that continued growth, investment, and coordination of research in this topic will ultimately yield robust biomarkers, clinically useful classification and staging algorithms, targetable pathways, pivotal clinical trials, and ultimately, cures. Here, we provide an overview of the clinical and scientific knowledge and its limitations around cancer cachexia.
© 2021 American Society for Parenteral and Enteral Nutrition.

Entities:  

Keywords:  animal models; anorexia; appetite; cachexia; cancer; malnutrition; nutrition

Mesh:

Year:  2021        PMID: 34897740      PMCID: PMC8756772          DOI: 10.1002/jpen.2287

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  127 in total

1.  Fenofibrate prevents skeletal muscle loss in mice with lung cancer.

Authors:  Marcus D Goncalves; Seo-Kyoung Hwang; Chantal Pauli; Charles J Murphy; Zhe Cheng; Benjamin D Hopkins; David Wu; Ryan M Loughran; Brooke M Emerling; Guoan Zhang; Douglas T Fearon; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

2.  Megestrol acetate-probably less effective than has been reported!

Authors:  Vicente Ruiz García; Oscar Juan
Journal:  J Pain Symptom Manage       Date:  2005-07       Impact factor: 3.612

Review 3.  Lessons from hereditary colorectal cancer.

Authors:  K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

Review 4.  Pancreatic Cancer-Induced Cachexia and Relevant Mouse Models.

Authors:  Sally E Henderson; Neil Makhijani; Thomas A Mace
Journal:  Pancreas       Date:  2018-09       Impact factor: 3.327

Review 5.  Definition and classification of cancer cachexia: an international consensus.

Authors:  Kenneth Fearon; Florian Strasser; Stefan D Anker; Ingvar Bosaeus; Eduardo Bruera; Robin L Fainsinger; Aminah Jatoi; Charles Loprinzi; Neil MacDonald; Giovanni Mantovani; Mellar Davis; Maurizio Muscaritoli; Faith Ottery; Lukas Radbruch; Paula Ravasco; Declan Walsh; Andrew Wilcock; Stein Kaasa; Vickie E Baracos
Journal:  Lancet Oncol       Date:  2011-02-04       Impact factor: 41.316

6.  Reduced rDNA transcription diminishes skeletal muscle ribosomal capacity and protein synthesis in cancer cachexia.

Authors:  Hyo-Gun Kim; Joshua R Huot; Fabrizio Pin; Bin Guo; Andrea Bonetto; Gustavo A Nader
Journal:  FASEB J       Date:  2021-02       Impact factor: 5.834

7.  Concurrent muscle and bone deterioration in a murine model of cancer cachexia.

Authors:  Eunhi Choi; Kadir Carruthers; Li Zhang; Nathan Thomas; Ricardo A Battaglino; Leslie R Morse; Jeffrey J Widrick
Journal:  Physiol Rep       Date:  2013-11-07

8.  Establishment and characterization of a novel murine model of pancreatic cancer cachexia.

Authors:  Katherine A Michaelis; Xinxia Zhu; Kevin G Burfeind; Stephanie M Krasnow; Peter R Levasseur; Terry K Morgan; Daniel L Marks
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-07-20       Impact factor: 12.910

9.  Modeling Human Cancer-induced Cachexia.

Authors:  Erin E Talbert; Maria C Cuitiño; Katherine J Ladner; Priyani V Rajasekerea; Melissa Siebert; Reena Shakya; Gustavo W Leone; Michael C Ostrowski; Brian Paleo; Noah Weisleder; Peter J Reiser; Amy Webb; Cynthia D Timmers; Daniel S Eiferman; David C Evans; Mary E Dillhoff; Carl R Schmidt; Denis C Guttridge
Journal:  Cell Rep       Date:  2019-08-06       Impact factor: 9.423

Review 10.  Diverging metabolic programmes and behaviours during states of starvation, protein malnutrition, and cachexia.

Authors:  Brennan Olson; Daniel L Marks; Aaron J Grossberg
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-09-28       Impact factor: 12.910

View more
  1 in total

1.  Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop.

Authors:  Jose M Garcia; Richard F Dunne; Kristen Santiago; Lisa Martin; Morris J Birnbaum; Jeffrey Crawford; Andrew E Hendifar; Martin Kochanczyk; Cassadie Moravek; Doris Piccinin; Vincent Picozzi; Eric J Roeland; Wendy K D Selig; Teresa A Zimmers
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-02-26       Impact factor: 12.063

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.